SEC Comment Letter for Allarity Therapeutics, Inc. (ALLR) (CIK 0001860657) (ALLR) — Jun 20, 2025

Allarity Therapeutics, Inc. (ALLR) (CIK 0001860657)
Date: June 20, 2025 · CIK: 0001860657 · Accession: 0000000000-25-006490

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

June 20, 2025

Author

Thomas H. Jensen

Form

UPLOAD

Company

Allarity Therapeutics, Inc. (ALLR) (CIK 0001860657)

Letter

June 20, 2025 Thomas H. Jensen Chief Executive Officer Allarity Therapeutics, Inc. 123 E Tarpon Ave Tarpon Springs, FL 34689 Re:Allarity Therapeutics, Inc. Draft Registration Statement on Form S-3 Submitted June 16, 2026 Cik No. 0001860657 Dear Thomas H. Jensen: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Arif Soto, Esq.

Show Raw Text

June 20, 2025
Thomas H. Jensen
Chief Executive Officer
Allarity Therapeutics, Inc.
123 E Tarpon Ave
Tarpon Springs, FL 34689
Re:Allarity Therapeutics, Inc.
Draft Registration Statement on Form S-3
Submitted June 16, 2026
Cik No. 0001860657
Dear Thomas H. Jensen:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement at least two business
days prior to the requested effective date and time. Please refer to Rules 460 and 461
regarding requests for acceleration. We remind you that the company and its management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Arif Soto, Esq.

SecProbe.io